We will focus mostly on the following guideline:
Q1D Bracketing and Matrixing Designs for Stability Testing of Drug Substances and Products (2003.2.7)
Key factors such as batch, strength, package size and fill can affect the specification attribute.
In addition to how the specification attribute may change with storage, these factors may have to be taken into consideration. For example if the % label claim is to considered in 3 batches and at 2 strengths then there is a total of 3 X 2 = 6 combinations. Each of these combinations may have to be monitored at each of 8 time points i.e. [0,3,6,9, 12, 18,24,36] months. Such a full study design would require at least 6 X 8 assays!
Requirements are specified in ICH Q1D A design in which samples for every factor combination are not tested at all time points. Two types of reduced design; “bracketing and “matrixing”. Can be applied to most types of drug products. For drug substances (APIs), matrixing is of limited applicability and bracketing is not generally applicable.
Bracketed designs are such that only samples at the extremes of certain design factors are tested at all times. This leads to economy on assay determinations but care must be taken as such reduced designs make assumptions that the assays either only increase or only decrease between the extremes. As an example lets look at the % label claim for three batches at 3 strengths and 3 container sizes. A full design would require 3 X 3 X 3 = 27 assays at any one time point.
A bracketed design using the extremes could reduce the design to only 12 assays:
Strength | Low | Medium | High |
Batch | 1 2 3 | 1 2 3 | 1 2 3 |
Small Container | T T T | — — — | T T T |
Medium Container | — — — | — — — | — — — |
Large Container | T T T | — — — | T T T |
Where ‘T’ denotes assay test and ‘–‘ denotes no assay test. This is a big saving on the number of assays to be undertaken but we would need to be confident that nothing unusual happens at the medium levels!
Bracketed designs can be applied as follows:
Matrixing designs are such that only a subset of all possible factor combinations may be collected at particular time points. At a subsequent time point a different subset of factor combinations are normally collected. Care must be taken in selecting the samples for testing to ensure the design is balanced and representative.
It is recommended that:
A matrix design with one half reduction on time points:
Time point (months) | 0 | 3 | 6 | 9 | 12 | 18 | 24 | 36 |
Strength Low | Half Data Collected | Half Data Collected | ||||||
Batch 1 | T | T | — | T | T | — | T | T |
Batch 2 | T | T | — | T | T | T | — | T |
Batch 3 | T | — | T | — | T | T | — | T |
Strength High | All Data Collected | All Data Collected | All Data Collected | |||||
Batch 1 | T | — | T | — | T | — | T | T |
Batch 2 | T | T | — | T | T | T | — | T |
Batch 3 | T | — | T | — | T | — | T | T |
Where ‘T’ denotes assay test and ‘–‘ denotes no assay test.
Matrixing designs are applicable if:
At first you will find it easier to use a full design. Use a bracket design when you are confident that nothing unusual happens between extremes. Use the matrix design to cut down on numbers of assays at each time point. Read the ICH Guidelines. These are not easy because of the many different factors that can effect storage and shelf life but after repeated reading it should fall into place.
NHS study finds that CT scan gets 70% of Lung Cancer at the Beginning Phase
How to Apply DQ/IQ/OQ/PQ in New Framework
Negotiations on Cost and Availability of New Pharmaceuticals
Covid-19 in China - Statistics & Facts
5 Health Care Stocks to Bet on as Coronavirus Woes Linger
Coronavirus Impact on the Tourism Industry Worldwide
Cold chain distribution; route qualification approaches
GAMP V computer system validation
Copyright © 2021 Paul R Palmer. All Rights Reserved. Company number 07509971. Designed and Developed by Gatitaa Technologies Pvt Ltd